Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

Core Insights - Zacks Premium provides tools for investors to enhance their stock market strategies and confidence, including daily updates, research reports, and stock screens [1] - The Zacks Style Scores are designed to rate stocks based on value, growth, and momentum, serving as complementary indicators to the Zacks Rank [2] Zacks Style Scores - Each stock receives a rating from A to F based on its value, growth, and momentum characteristics, with higher scores indicating a better chance of outperforming the market [3] - The Value Score identifies attractive and discounted stocks using various financial ratios, appealing to value investors [4] - The Growth Score focuses on a company's future prospects and financial health, analyzing earnings, sales, and cash flow for sustainable growth [5] - The Momentum Score helps investors capitalize on price trends by assessing recent price changes and earnings estimate revisions [6] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors seeking the best value, growth, and momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to assist investors in building successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal investment potential [9] Stock Analysis: Bristol Myers Squibb (BMY) - Bristol Myers Squibb is a leading biopharmaceutical company focused on treatments for severe diseases, with notable products like Opdivo and a diverse portfolio including immunology and cardiovascular drugs [11] - BMY holds a 3 (Hold) rating on the Zacks Rank, with a VGM Score of A and a Value Style Score of B, indicating attractive valuation metrics such as a forward P/E ratio of 7.23 [12] - Recent upward revisions in earnings estimates and a Zacks Consensus Estimate of $6.77 per share for fiscal 2025, along with an average earnings surprise of 16.2%, make BMY a stock of interest for investors [12][13]